Key result
Ranolazine significantly inhibited the activity of β-oxidation enzymes in normal rat hearts, but had significantly less inhibitory effect on these enzymes in diabetic rat hearts.
Why the study?
Does ranolazine inhibit mitochondrial beta-oxidation enzymes in streptozotocin-induced diabetic rat hearts compared to normal rat hearts?
Does ranolazine inhibit mitochondrial beta-oxidation enzymes in streptozotocin-induced diabetic rat hearts compared to normal rat hearts?
The clinical efficacy of ranolazine in diabetic patients is likely associated with mechanisms other than the inhibition of the beta-oxidation pathway, as it showed no significant inhibition of these enzymes in diabetic rat hearts.
Answers are grounded in this paper and cite their sources.
May question beta-oxidation inhibition as ranolazine mechanism in diabetes; hypothesis-generating for alternative pathways and human studies.
Backgrounds: Ranolazine had two main functions: blocking cardiac late sodium channels and / or inhibition of 3ketoacyl coenzyme A thiolase, an important enzyme in -oxidation of fatty acids. Diabetic cardiomyopathy is a complication, defined as cardiac dysfunction without the involvement of epicardial vessels. In this study, the effect of ranolazine on fatty acid oxidation was investigated in diabetic rats induced by streptozotocin.
No takes yet. Share an insight, caveat, or question.
Khazraei et al. (2016) studied Diabetic cardiomyopathy (n=14). Ranolazine vs. Absence of ranolazine / Normal rat hearts was evaluated on Activity of mitochondrial β-oxidation enzymes (hydratase, dehydrogenase, thiolase) (p=<0.05). Ranolazine significantly inhibited the activity of β-oxidation enzymes in normal rat hearts, but had significantly less inhibitory effect on these enzymes in diabetic rat hearts.
Synapse has enriched 10 related papers. Consider them for comparative context: